Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models

European Journal of Surgical Oncology

Volumn 31, Issue 9, 2005, Pages 1042-1050

  Williams, R N ^a   Parsons, S L ^a   Morris, T M ^a   Rowlands, B J ^a   Watson, Sue A ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Angiotensin converting enzyme; Captopril; Gastric cancer; Matrix metalloproteinases

Indexed keywords

CAPTOPRIL; CISPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATIN; GELATINASE A; GELATINASE B; MATRIGEL; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN FAMILY; STOMACH ADENOCARCINOMA; TUMOR CELL LINE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 27944509143     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2005.04.003     Document Type: Article

References (47)

1. P.D. Brown Matrix metalloproteinases in gastrointestinal cancer Gut 43 1998 161-163
2. N.D. Rawlings A.J. Barrett Evolutionary families of peptidases Biochem J 290 1993 205-218
3. L.M. Coussens Z. Werb Matrix metalloproteinases and the development of cancer Chem Biol 3 1996 895-904
4. W.G. Stetler-Stevenson A.E. Yu Proteases in invasion: Matrix metalloproteinases Semin Cancer Biol 11 2001 143-152
5. G. Murphy Matrix metalloproteinases and their inhibitors Acta Orthop Scand Suppl 66 1995 55-60
6. T. Itoh M. Tanioka H. Yoshida T. Yoshioka H. Nishimoto S. Itohara Reduced angiogenesis and tumor progression in gelatinase A-deficient mice Cancer Res 58 1998 1048-1051
7. J. Fang Y. Shing D. Wiederschain L. Yan C. Butterfield G. Jackson et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model Proc Natl Acad Sci USA 97 2000 3884-3889
8. A. Albini A. Melchiori L. Santi L.A. Liotta P.D. Brown W.G. Stetler-Stevenson Tumor cell invasion inhibited by TIMP-2 J Natl Cancer Inst 83 1991 775-779
9. G.K. Schwartz H. Wang N. Lampen N. Altorki D. Kelsen A.P. Albino Defining the invasive phenotype of proximal gastric cancer cells Cancer 73 1994 22-27
10. H. Kawamata K. Kawai S. Kameyama M.D. Johnson W.G. Stetler-Stevenson R. Oyasu Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma Int J Cancer 63 1995 680-687
11. H. Kawamata S. Kameyama K. Kawai Y. Tanaka L. Nan D.H. Barch et al. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A Int J Cancer 63 1995 568-575
12. A.R. Nelson B. Fingleton M.L. Rothenberg L.M. Matrisian Matrix metalloproteinases: Biologic activity and clinical implications J Clin Oncol 18 2000 1135-1149
13. H.M. Collins T.M. Morris S.A. Watson Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase Br J Cancer 84 2001 1664-1670
14. A. D'Errico S. Garbisa L.A. Liotta V. Castronovo W.G. Stetler-Stevenson W.F. Grigioni Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression Mod Pathol 4 1991 239-246
15. W.F. Grigioni A. D'Errico C. Fortunato M. Fiorentino A.M. Mancini W.G. Stetler-Stevenson et al. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane Mod Pathol 7 1994 220-225
16. M.S. O'Reilly L. Holmgren Y. Shing C. Chen R.A. Rosenthal M. Moses et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 1994 315-328
17. M.S. O'Reilly D. Wiederschain W.G. Stetler-Stevenson J. Folkman M.A. Moses Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance J Biol Chem 274 1999 29568-29571
18. T. Suzuki Y. Kuwabara H. Iwata M. Mitani N. Shinoda A. Sato et al. Role of matrix metalloproteinase-9 in in vitro invasion of esophageal carcinoma cells J Surg Oncol 81 2002 80-86
19. J.J. Peschon J.L. Slack P. Reddy K.L. Stocking S.W. Sunnarborg D.C. Lee et al. An essential role for ectodomain shedding in mammalian development Science 282 1998 1281-1284
20. J. Folkman Tumor angiogenesis: Therapeutic implications N Engl J Med 285 1971 1182-1186
21. G. Taraboletti A. Garofalo D. Belotti T. Drudis P. Borsotti E. Scanziani et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases J Natl Cancer Inst 87 1995 293-298
22. B. Davies P.D. Brown N. East M.J. Crimmin F.R. Balkwill A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts Cancer Res 53 1993 2087-2091
23. G.W. Sledge Jr M. Qulali R. Goulet E.A. Bone R. Fife Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice J Natl Cancer Inst 87 1995 1546-1550
24. S.A. Watson T.M. Morris G. Robinson M.J. Crimmin P.D. Brown J.D. Hardcastle Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models Cancer Res 55 1995 3629-3633
25. M. Betz P. Huxley S.J. Davies Y. Mushtaq M. Pieper H. Tschesche et al. 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile Eur J Biochem 247 1997 356-363
26. R. Giavazzi G. Taraboletti Preclinical development of metalloproteasis inhibitors in cancer therapy Crit Rev Oncol Hematol 37 2001 53-60
27. D.W. Cushman M.A. Ondetti History of the design of captopril and related inhibitors of angiotensin converting enzyme Hypertension 17 1991 589-592
28. O.V. Volpert W.F. Ward M.W. Lingen L. Chesler D.B. Solt M.D. Johnson et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats J Clin Invest 98 1996 671-679
29. C. Prontera B. Mariani C. Rossi A. Poggi D. Rotilio Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma Int J Cancer 81 1999 761-766
30. J.R. Jonsson A.D. Clouston Y. Ando L.I. Keleman M.J. Horn M.D. Adamson et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis Gastroenterology 121 2001 148-155
31. H. Li H. Simon T.M. Bocan J.T. Peterson MMP/TIMP expression in spontaneously hypertensive heart failure rats: The effect of ACE- and MMP-inhibition Cardiovasc Res 46 2000 298-306
32. S.A. Watson L.J. Wilkinson J.F. Robertson J.D. Hardcastle Effect of histamine on the growth of human gastrointestinal tumours: Reversal by cimetidine Gut 34 1993 1091-1096
33. P.D. Brown A.T. Levy I.M. Margulies L.A. Liotta W.G. Stetler-Stevenson Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines Cancer Res 50 1990 6184-6191
34. N.J. Marshall C.J. Goodwin S.J. Holt A critical assessment of the use of microculture tetrazolium assays to measure cell growth and function Growth Regul 5 1995 69-84
35. S.A. Watson L.G. Durrant P.M. Wencyk A.L. Watson D.L. Morris Intracellular gastrin in human gastrointestinal tumor cells J Natl Cancer Inst 83 1991 866-871
36. D.F. McWilliams S.A. Watson D.M. Crosbee D. Michaeli T. Seth Coexpression of gastrin and gastrin receptors (CCK-B and DCCK-B) in gastrointestinal tumour cell lines Gut 42 1998 795-798
37. J.M. McLaughlan R. Seth G. Vautier R.A. Robins B.B. Scott C.J. Hawkey et al. Interleukin-8 and inducible nitric oxide synthase mRNA levels in inflammatory bowel disease at first presentation J Pathol 181 1997 87-92
38. S.A. Watson T.M. Morris H.M. Collins L.J. Bawden K. Hawkins E.A. Bone Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: Relationship with levels of circulating CEA Br J Cancer 81 1999 19-23
39. S.I. Hii D.L. Nicol D.C. Gotley L.C. Thompson M.K. Green J.R. Jonsson Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma Br J Cancer 77 1998 880-883
40. Y. Sakurai T. Uraguchi H. Imazu S. Hasegawa T. Matsubara M. Ochiai et al. Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU Gastric Cancer 7 2004 110-116
41. K.P. Ohman B. Kagedal R. Larsson B.E. Karlberg Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake J Cardiovasc Pharmacol 7 Suppl 1 1985 S20-S24
42. T. Nakagawa T. Kubota M. Kabuto T. Kodera Captopril inhibits glioma cell invasion in vitro: Involvement of matrix metalloproteinases Anticancer Res 15 1995 1985-1989
43. D. Sorbi M. Fadly R. Hicks S. Alexander L. Arbeit Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases Kidney Int 44 1993 1266-1272
44. H.K. Rooprai A. Kandanearatchi S.L. Maidment M. Christidou G. Trillo-Pazos D.T. Dexter et al. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro Neuropathol Appl Neurobiol 27 2001 29-39
45. H. Yoshiji S. Kuriyama M. Kawata J. Yoshii Y. Ikenaka R. Noguchi et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor Clin Cancer Res 7 2001 1073-1078
46. M.L. Coker J.R. Jolly C. Joffs T. Etoh J.R. Holder B.R. Bond et al. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation Am J Physiol Heart Circ Physiol 281 2001 H543-H551
47. A.F. Lever D.J. Hole C.R. Gillis I.R. McCallum G.T. McInnes P.L. MacKinnon et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352 1998 179-184